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A B S T R A C T
Low/no-calorie sweeteners (LNCS) are continually under the spotlight in terms of their safety and benefits; in 2014 a study was published linking LNCS to an
enhanced risk of glucose intolerance through modulation of the gut microbiota. In response, an in-depth review of the literature was undertaken to evaluate the
major contributors to potential changes in the gut microbiota and their corresponding sequelae, and to determine if consuming LNCS (e.g., acesulfame K, aspartame,
cyclamate, neotame, saccharin, sucralose, steviol glycosides) contributes to changes in the microbiome based on the data reported in human and animal studies. A
few rodent studies with saccharin have reported changes in the gut microbiome, but primarily at high doses that bear no relevance to human consumption. This and
other studies suggesting an effect of LNCS on the gut microbiota were found to show no evidence of an actual adverse effect on human health. The sum of the data
provides clear evidence that changes in the diet unrelated to LNCS consumption are likely the major determinants of change in gut microbiota numbers and phyla,
confirming the viewpoint supported by all the major international food safety and health regulatory authorities that LNCS are safe at currently approved levels.
1. Introduction
The trillions of symbiotic microorganisms present in the human
body, the majority of which are located within the gastrointestinal
tract, are collectively referred to as the microbiota. The human gut
microbiota is seeded at birth, develops intensely during the first 3 years
of life, and continues to evolve and adapt throughout the lifetime of an
individual (Koenig et al., 2011). The gene set of the gut microbiota (the
gut microbiome) is estimated to be about 3 million genes, about 150
times larger than that of the human genome ((Qin et al., 2010). Over
1000 species have been identified in total, with around 160 being
present in the gut of any one individual (Rajilic-Stojanovic and De Vos,
2014). The predominant phyla, which encompass about 90% of the
bacteria, are Firmicutes and Bacteroidetes; other common phyla include
Actinobacteria, Proteobacteria, Verrucomicrobia, and Fusobacteria, to-
gether with a limited number of species (mostly methanogens) that fall
into the domain Archaea (Eckburg et al., 2005). The relative propor-
tions of these phyla and the species present can vary enormously be-
tween individuals and the exact contributions of a variety of factors to
this diversity, as well as to the initial development and continuing
evolution of the gut microbiota, including host genetics, environmental
elements, and diet, remain to be elucidated (Tilg and Kaser, 2011;
Ursell et al., 2012; Xu and Knight, 2015). Mounting evidence, however,
indicates that diet, both habitual, and long-term and shorter-term
dietary changes, appear to be the most significant factors influencing
the overall composition of the gut microbiota and its functionality
(Muegge et al., 2011; Wu et al., 2011; David et al., 2014; Graf et al.,
2015).
In addition to its taxonomic diversity, the gut microbial community
has an equally extensive metabolic repertoire including hydrolysis, re-
duction, dehydroxylation, deamination, and ring fission that comple-
ments the activity of mammalian enzymes in the liver and gut mucosa
(Nicholson et al., 2012). The human gut microbiota makes an important
contribution to the breakdown, absorption, and metabolism of key
dietary components by contributing enzymes that are not encoded by
the human genome. These enzymes contribute to the breakdown of
polysaccharides, polyphenols, and the synthesis of vitamins. In turn, the
microbiota composition and activities can be influenced by diet. Dietary
components of particular importance in modulating the microbiota are
those that are poorly digested in the stomach and small intestine, such
as dietary fiber, and hence, reach the colon where they become sub-
strates for microbial fermentation.
The impact of consuming sweeteners on the gut microbiota has
recently received significant media attention as a result of a 2014 study
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reported by Suez et al. (2014). The authors of this study concluded that
consumption of low/no-calorie sweeteners (LNCS) modulates the
composition and function of the gut microbiota, leading to enhanced
risk of glucose intolerance. Critical review of this paper, however, has
revealed a number of limitations in experimental design and issues in
both the analysis and reporting of the study data, bringing into question
the conclusions drawn by the authors (Magnuson, 2015). The purpose
of the present review is to (a) discuss known major contributors to gut
microbiota fluctuations to give context to the outcomes of studies on
LNCS, and (b) survey and assess the scientific literature relevant to the
potential for LNCS to affect the gut microbiota, with particular regard
to the potential for any adverse health outcome. This included studies
on acesulfame potassium (acesulfame K), aspartame, cyclamate, neo-
tame, saccharin, sucralose, and rebaudioside A.
2. The effects of dietary composition on the gut microbiota
2.1. Methods for studying the gut microbiota
The methodology for analyzing the composition of the gut micro-
biota has seen great advances over the last 10–20 years. Traditional
approaches were based on cultivation of fecal organisms which were
time consuming and insensitive and required fecal samples to be stored
and processed in specialized anaerobic culture systems (Sankar et al.,
2015). The advent of high-throughput DNA sequencing technologies
has provided insights into gut microbial ecology without the need for
cultivation and has revealed the complexity and diversity of the mi-
crobiota. It is estimated that only about 30% of the human gut micro-
biota can currently be cultured. A wide range of techniques are now
available to explore the gut microbiota and these have been applied to
studies of dietary effects and the relationship of microbiota composition
in health and disease (Morgan and Huttenhower, 2012). It should be
noted that differences in DNA extraction and recovery, sequencing
technology, and polymerase chain reaction (PCR) amplification can
affect the recovery of different groups of bacteria, and lead to incon-
sistencies between studies (Kennedy et al., 2014; Walker et al., 2014).
Furthermore, each of the methods has inherent advantages and dis-
advantages, which have been reviewed by Sankar et al. (2015). The
molecular approaches broadly divide into shotgun metagenomic se-
quencing and 16S ribosomal RNA (rRNA) methods. Whole community
shotgun sequencing of all DNA fragments in a sample is a very powerful
technique especially with the latest high throughput methods, which
allows the production of large metagenomic datasets from a large
number of individual samples such as those generated by the Human
Microbiome Project and MetaHIT programs. The method can provide
information on microbial diversity and metabolic function as well as
the relationship to health and diseases such as inflammatory bowel
disease, diabetes, and obesity (Sankar et al., 2015; Walker et al., 2015).
The method does have limitations, including for example, that (a) some
of the reads cannot be assigned a taxonomic identification or function
where species are in low abundance, (b) gene prediction is dependent
on the read length, and (c) insufficient reference databases currently
exist.
Analyses based on PCR amplification of sequences from the 16S
rRNA gene, which is present in all bacteria and archaea, can provide a
more targeted approach to characterizing the gut microbial community.
The 16S rRNA gene provides the basis for fluorescence in situ hy-
bridization (FISH) and quantitative PCR and microarray methods such
as the Human Intestinal Tract Chip (HITChip), which can detect less
abundant, but nevertheless potentially important, microbial groups
(Morgan and Huttenhower, 2012; Walker et al., 2015). Again, the
methods do have limitations including biases in DNA recovery and PCR
amplification that can have differential effects on bacterial groups,
limitations in the reference databases, and relatively low resolution at
species level than at higher taxonomic levels (Graf et al., 2015; Sankar
et al., 2015).
2.2. Effect of different dietary components and dietary composition on
microbiota
Two main mechanisms are proposed to underlie the modulation of
microbiota composition by diet (Flint et al., 2015). Firstly, the diversity
in composition of the microbiota is reflected in great metabolic di-
versity, with the various microbial types exhibiting different abilities to
utilize substrates reaching the colon. Thus, the availability of particular
substrates can favor growth of those genera or species capable of ex-
ploiting them. This mechanism is especially relevant to the effects of
fermentable fibers, resistant starches, and oligosaccharides, which are
poorly digested in the upper gastrointestinal tract and hence reach the
large bowel and provide substrates for intestinal bacterial fermentation.
A second mechanism by which diet may alter microbiota composition is
via the modulation of physico-chemical conditions in the gut since
microbial species differ in their tolerance of environmental factors such
as pH and bile salts (Flint et al., 2015). Both mechanisms seem to play a
role in determining the response of the microbiota to dietary compo-
sition.
There is evidence for the effects of both long-term and short-term
diets on gut microbial composition and metabolism. The evidence for a
role of long-term, habitual dietary intake is indirect and derived from
observational studies of human population groups. For example, in a
survey of adults from the United States, Wu et al. (2011) found asso-
ciations between high levels of fecal Prevotella and consumption of
dietary fiber, whereas high numbers of Bacteroides were associated with
protein and fat intake. A positive association of Prevotella abundance
with habitual dietary fiber intake was also noted by David et al. (2014)
in a United States cohort. These data are consistent with a previous
study comparing fecal microbiotas of rural African children with those
from Italy (De Filippo et al., 2010). The former exhibited a greater
abundance of Prevotella and the latter more Bacteroides, potentially
reflecting the higher fiber intake of rural Africans and higher fat and
protein intake of the western diet. There are a few observational studies
of vegetarians and omnivores, and although these studies have in-
dicated differences in microbiota composition, there is little consistency
probably due in part to the studies being conducted in different coun-
tries as well as various limitations in study design (reviewed by Graf
et al., 2015).
The susceptibility of the gut microbiota to shorter term dietary
change has been explored in a number of human intervention studies,
some of which have involved gross dietary changes such as animal-
versus plant-based diets, while others have focused on changes in spe-
cific dietary components (e.g., resistant starch). David et al. (2014)
conducted a study in which 10 subjects consumed either an animal-
based diet (meat, eggs, and cheese) or a plant-based diet (rich in le-
gumes, grains fruits, and vegetables) for 5 days with a 6-day washout
period. Fecal microbiota diversity and composition were assessed by
16S rRNA gene sequencing. In comparison to the subjects' baseline
diets, the animal-based diet increased fat and protein intake by 2-fold
and decreased fiber intake to virtually zero and was associated with
significant changes in relative abundance of 22 bacterial taxonomic
clusters. This diet increased the abundance of bile-tolerant microbes,
notably species of Alstipes, Bilophila, Bacteroides, and decreased levels of
Roseburia, Eubacterium, and Ruminococcus that ferment plant poly-
saccharides. The plant-based diet, which increased fiber intake nearly
3-fold to 25 g/1000 kcal and decreased protein and fat consumption,
had less potent effects on the microbiota with only 3 taxonomic clusters
being affected. Klinder et al. (2016) conducted a randomized controlled
trial in which fruit and vegetable intake was increased by up to 6
portions a day and at this level of intake an increase in Clostidium
leptum-Ruminococcus bromii/flavefaciens group was seen. Salonen et al.
(2014) reported a cross-over study of 14 obese men fed 3 fully-con-
trolled diets for 3 weeks each: a diet high in resistant starch (RS); a diet
high in wheat bran, providing non-starch polysaccharides (NSP), but
otherwise of similar macronutrient composition; and a high protein
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weight loss diet. Microbiota analysis was by phylogenetic microarray
(HITChip) and by quantitative PCR analysis. Despite the diet type ex-
plaining only 10% of the total variance (less than that between subjects)
each one induced distinct changes. In particular, increases in Rumino-
coccaceae phylotypes (Clostridium leptum, C. cellulosi, Oscillospira spp.)
and certain Bacteroidetes were evident during the RS diet period,
whereas on the NSP diet, Lachnospiraceae phylotypes increased and
members of Ruminococcaceae decreased. During the weight loss diet,
bifidobacteria decreased. Importantly, the dietary responsiveness of
each individual's microbiota varied considerably, suggesting that in-
dividuals can be divided into responders and non-responders based on
certain features of their gut microbiota. In these subjects, a low re-
sponse to dietary change was associated with microbiotas with high
phylogenetic diversity, which may promote higher stability of the
ecosystem. Diversity, however, may not be a universal predictor of
dietary responsiveness, as a study of obese subjects from Belgium,
Finland, and the United Kingdom identified the main predictors to be
the abundance of certain Firmicutes phylotypes, particularly those in
clostridial clusters IV, IX, and XIV, and not microbiota diversity
(Korpela et al., 2014). One reason why certain gut microbes respond to
dietary change in some individuals but not others may be related to
baseline abundance. This has been demonstrated for bifidobacteria
stimulation by prebiotics, which is more apparent when baseline
numbers are low (Tuohy et al., 2001). Several studies have also in-
vestigated the impact of overall calorie reduction on gut microbial
composition, primarily in populations of obese adults (reviewed by
M.C. Dao et al., 2016). Changing between diets higher in calories/en-
ergy (i.e., higher in carbohydrate and/or fat) to those with lower caloric
content (i.e., higher in protein and/or fiber) consistently results in
modulation of the gut microbiota, including shifts in specific bacterial
phyla and/or overall microbial diversity.
Whole grain products, including maize, wheat, barley, and rice,
have been the focus of a number of human trials. In general, these
studies revealed increases in bifidobacteria and the proportion of
Lactobacillus/Enterococcus group (Carvalho-Wells et al., 2010; Costabile
et al., 2012) with 1 study (Martínez et al., 2013) also showing an in-
crease in Firmicutes (Blautia and Roseburia). Increases in bifidobacteria
were also apparent in studies of phytochemical rich foods such as
blueberries, red wine, and cocoa polyphenols (Tzounis et al., 2011;
Vendrame et al., 2011; Queipo-Ortuño et al., 2012). The main bifido-
genic food components are the non-digestible oligosaccharides, such as
fructo-oligosaccharides, galacto-oligosaccharides, xylo-oligosacchar-
ides, and inulin, usually referred to as prebiotics. Numerous controlled
dietary trials in young and old adults as well as children have demon-
strated increases in numbers of bifidobacteria after prebiotic con-
sumption (reviewed by Rastall and Gibson, 2015). In some studies
numbers of other bacterial groups, such as lactobacilli, change, but
bifidobacteria increases are the most consistent (Graf et al., 2015).
Other non-digestible carbohydrates that have been investigated in
human trials include polydextrose, soluble corn fiber, and resistant
maltodextrin. Intake of polydextrose or corn fiber for 21 days increased
the concentration of Clostridiaceae and Eubacteriaceae and also in-
creased the abundance of Faecalibacterium, Phascolarctobacterium, and
Dialister (Hooda et al., 2012). A second study of polydextrose given for
3 weeks reported increases in Ruminococcus intestinalis and in Clos-
tridium clusters I, II, and IV (Costabile et al., 2012). It is important to
note that dietary interventions can have a significant impact on mi-
crobiota functions, even without major changes in composition. In the
study by David et al. (2014) on animal- and plant-based diets, the gene
expression profile was strongly linked to diet type and was associated
with changes in carbohydrate and protein fermentation, as well as vi-
tamin synthesis. Their data suggested that gene expression differences
were due to both regulatory and taxonomic shifts within the micro-
biota.
Overall, the dietary studies indicate that the composition and
functionality of the microbiota are modified by dietary changes and
that there can be important inter-individual differences in the response
of gut microbiotas, thereby making it difficult to generalize about the
influence of specific dietary components. As a consequence, it is clear
that when conducting dietary intervention studies to assess the effects
of various ingredients that are added to the diet in small amounts, such
as LNCS, the habitual diet of the subjects should be well-characterized
and the intervention diets should be carefully controlled.
3. Review of the scientific literature: low/no-calorie sweetener
exposure and impact on the gut microbiota
To investigate whether an association exists between LNCS con-
sumption and changes in the composition of the gut microbiota a lit-
erature search was conducted using ProQuest to identify publications
studying sweeteners (“high-intensity” or “high-potency” or “intense” or
“artificial” or “low-calorie" or “non-caloric" or “no-calorie” or “non-
nutritive” sweetener) and the gut microbiota (gut or intestinal “mi-
crobiome” or “microbiota” or “microbes” or “microflora” or “micro-
organisms”). Specific sweetener names were also used in the search as
follows: Aspartame or Nutrasweet; or Sucralose or Splenda; or
Saccharin or SugarTwin or “Sweet’N Low”; or “Acesulfame potassium”
or “Acesulfame K” or Ace-K; or Sunett or “Sweet One”; or Neotame or
Advantame; or Stevia or “Steviol glycosides” or “Rebaudioside A” or
“Stevioside” or PureVia or Truvia; or Mogrosides; or Nectresse or
“Norbu Sweetener”; or Cyclamate. Applying first the sweetener search
terms followed by the gut microbiota search terms, the following da-
tabases were queried on 18 May 2018 (with no date restrictions, for all
languages, for all article types including both peer-reviewed and non-
peer-reviewed [e.g., research articles, reviews, conference abstracts,
news articles, interviews, and book chapters]): AdisInsight: Trials,
AGRICOLA, AGRIS, Allied & Complementary Medicine™, BIOSIS®
Toxicology, BIOSIS Previews®, CAB ABSTRACTS, Embase®, Foodline®:
SCIENCE, FSTA®, MEDLINE®, NTIS: National Technical Information
Service, and ToxFile®. The search generated 123 hits and all articles
were screened for relevance based on the following inclusion criteria:
(a) in vivo studies conducted in animals and humans (all in vitro studies
were excluded); and (b) oral exposure to 1 or more LNCS, and (c) re-
ported measurement of microbial populations in the gut. Published
abstracts from presentations and/or conferences were matched with full
articles, where applicable, and remaining abstracts were included in the
search results so long as criteria (a), (b), and (c) listed above were met.
Review articles and opinion pieces responding to recent publications in
the field were excluded; however, where applicable, reference lists were
reviewed for additional relevant publications. Following application of
the defined screening criteria, 17 publications were identified as re-
levant primary research articles investigating the administration of
LNCS to animals or humans and effects on the gut microbiota. The
experimental details and outcomes of these studies, including study
size, subjects, interventions, comparisons, outcomes related to the gut
microbiota, and study design, are summarized and grouped by sweet-
ener below. For publications that investigated more than one single
LNCS, the results have been evaluated on a per sweetener basis and are
reported individually in the respective subsections below. A summary
of all identified studies, including study design, microbiome-related
results, and potential confounding factors, is presented for comparison
in Table 1.
3.1. Acesulfame potassium (acesulfame K)
Acesulfame K was administered to CD-1 mice (N=5 per sex per
group) via gavage for 4 weeks at a dose of 37.5 mg/kg/day, and the
control group received only water (Bian et al., 2017a). Fecal samples
were collected after 4 weeks for 16S rRNA gene sequencing and func-
tional gene enrichment analysis. The authors reported that weight gain
from baseline to the end of the study increased significantly in males
compared to the respective control group, but not in females. No data
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on food consumption monitoring, however, was provided so it is un-
clear if this group may have consumed more chow. The relative
abundance of Bacteroides, Anaerostipes, and Sutterella significantly in-
creased in male mice, whereas in female mice Lactobacillus, Clostridium,
an unassigned Ruminococcaceae genus and an unassigned Oxalobacter-
aceae genus decreased, and Mucispirillum increased. Despite these
findings in the gut microbiome, several limitations are discussed by the
authors and include the use of a high dose of acesulfame K (2.5x the
acceptable daily intake [ADI]), lack of food intake monitoring, and
small sample size, and the authors indicate that ongoing studies have
been designed to address these shortcomings.
Uebanso et al. conducted a study with male C57Bl/6J mice and
exposed them to acesulfame K in the drinking water for 8 weeks
(N=9) (Uebanso et al., 2017). Control mice (N=8) received distilled
water, and the authors measured body weight and fluid intake and
reported an average exposure of 12.9 mg/kg/day for the acesulfame K
group over the course of the study. Liquid and energy consumption was
monitored and reported to be equivalent between the control and
acesulfame K groups. Fecal samples and cecal contents were obtained at
the end of the study for 16S rRNA analysis, and the relative amounts of
total bacteria, Firmicutes, Bacteroidetes, Bacteroides, Clostridium IV and
Clostridium IVXa were equivalent between groups. Furthermore, the
relative band intensities of different 16S rRNAs from the V2 to V3 re-
gion for the cecal contents as well as the feces were not changed fol-
lowing acesulfame K exposure. The authors concluded that acesulfame
K did not significantly alter the gut microbiota in mice exposed to doses
equivalent to the human ADI.
The effects of acesulfame K on the gut microbiota was investigated
in a cross sectional clinical study, where participants completed a daily
food record for 4 days and fecal samples were collected on the fifth day
to assess gut microbial composition by 16S rRNA analysis (Frankenfeld
et al., 2015). Of the 31 participants in the study, 7 reported consump-
tion of acesulfame K over the 4-day period in amounts of 1.7–33.2mg/
day (“consumers”). Consumers that reported consuming both ace-
sulfame K and aspartame were analyzed separately. The median percent
abundance of bacteria at the order and class level was compared be-
tween consumers and non-consumers of acesulfame K and no sig-
nificant differences were found. The median Bacteroidetes:Firmicutes
ratio remained constant between the 2 groups, whereas statistically
significant differences in bacterial diversity evaluated with UniFrac
analysis were noted across consumers and non-consumers. Given that
habitual diet was not controlled for it is probable that the difference
between the 2 groups was related to diet alone and as such it is not
possible to come to any conclusion regarding the impact of acesulfame
K on the gut microbiota.
3.2. Aspartame
Aspartame's effects on the gut microbiota were also investigated in
the cross sectional clinical study described above for acesulfame K
(Frankenfeld et al., 2015). Of the 31 participants in the study, 7 were
found to consume 5.3–1112mg/day of aspartame over the 4-day study
period (“consumers”). These were 7 different individuals from those
described in Section 3.1 that consumed acesulfame K, and co-con-
sumers of both sweeteners, which were analyzed separately. Similar to
what was reported for acesulfame K, no significant differences between
consumers and non-consumers were found for the median percent
abundance of bacteria at the order and class level, and the median
Bacteroidetes:Firmicutes ratio did not change between the 2 groups.
Statistically significant differences in bacterial diversity were noted
across aspartame consumers and non-consumers, though as outlined
above, the significance of this finding can be called in to question as
habitual diet was not controlled for between the 2 groups.
The effect of aspartame consumption on the composition of the gut
microbiota of male Sprague-Dawley rats (N=10 to 12 per group), with
and without diet-induced obesity, was assessed over 8 weeks (PalmnäsTa
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et al., 2014). Aspartame was administered in the drinking water at a
dose of 5mg/kg/day to the rats with diet-induced obesity and 7mg/kg/
day to those without diet-induced obesity. Control animals consumed
only water. Fecal samples were collected at the end of the study and
evaluated by 16S rRNA analysis. The only significant change observed
in the normal weight rats fed aspartame was an increase in the levels of
Clostridium leptum compared to the normal weight control group. More
changes in the composition of the gut microbiota of the obese rats fed
aspartame compared to the obese control group were reported, in-
cluding increased total bacteria, Bifidobacterium spp., En-
terobacteriaceae, C. leptum, and Roseburia spp. Unfortunately, fecal
samples were not analyzed prior to dosing so it is unclear if these dif-
ferences were due to the administration of the sweetener or were in-
herent differences in the gut microbiota between obese and normal
weight animals. The study would have been more informative if it had
measured the microbiota changes over the 8-week intervention period
between treatment groups. In addition, large differences were noted
with respect to food and water consumption by both normal weight and
obese rats fed aspartame compared to their respective control groups;
all aspartame-exposed rats ate less food, therefore consuming fewer
kcal per day, and drank more water compared to their respective con-
trol groups. As discussed in Section 2, differences in food consumption
and caloric intake influence the composition of the gut microbiota, and
therefore without the inclusion of an isocaloric control group, the re-
ported changes in gut microbial composition cannot be attributed to
aspartame due to the limitations in study design.
A study published by Suez et al. (2014) investigated the impact of
low-calorie sweetener exposure first on glucose metabolism and then
extended some studies to include analysis of the intestinal microbiota.
Commercial aspartame (Sweet'n Low Gold, 4% aspartame) was ad-
ministered to C57Bl/6 male mice (N=20) in the drinking water for 11
weeks, providing an approximate daily dose of 1333mg/kg aspartame
(approximately 30 times higher than the ADI of 40mg/kg/day), as
estimated from the liquid intake data reported in the supplemental
data. Saccharin and sucralose were also investigated and the results for
these compounds are discussed in their respective Sections 3.4 and 3.5
below. Control groups (N=20 per group) consumed water, sucrose
(33 g/kg/day), or glucose (50 g/kg/day). To detect changes in glucose
metabolism, an oral glucose tolerance test (OGTT) was administered at
the end of the study and glycemic response was calculated as the area
under the 2-h blood glucose response curve. No baseline OGTT results
were reported. The statistical analysis grouped all data for the low-
calorie sweeteners together (aspartame, saccharin, and sucralose) and
compared this group to all control data (water, sucrose, and glucose);
glycemic response was reported to be significantly higher in the low-
calorie sweetener group (P < 0.001). Scientific justification for this
mass grouping of data was not provided by the authors, yet, based on
this statistical assessment they concluded that “artificial sweeteners
induce glucose intolerance”. Furthermore, the reported median and
range of the aspartame data set was not visually different from that for
the water, sucrose, and glucose control data sets, suggesting that as-
partame itself had no effect on glycemic responses. The authors asserted
that aspartame affected the gut microbiota, based on a reported in-
crease in glucose response to a single OGTT in mice receiving a com-
mercial formulation of aspartame in the drinking water for 11 weeks,
which was not seen when the mice were treated with antibiotics.
However, the study had no actual measure of microbiota in mice ad-
ministered aspartame alone. Furthermore, the lack of change in the
post-prandial response to the OGTT when aspartame-treated mice were
given antibiotics is insufficient evidence to conclude that there was an
effect on the gut microbiota.
3.3. Cyclamate
A number of studies show that cyclamate may be converted by the
gut microbiota to cyclohexylamine, which is absorbed and excreted in
urine. One study also assessed the effect of cyclamate ingestion on the
distribution of fecal microbiota in vivo. In this study, a Macaca irus
monkey was orally administered 250mg/kg/day sodium cyclamate for
30 days (Matsui et al., 1976). Urine samples from this monkey con-
firmed a significant conversion of the ingested cyclamate to cyclohex-
ylamine. The control group consisted of 3 monkeys (2 M. rhesus, 1
Cynopithecus niger) that did not consume sodium cyclamate. Fecal
samples were collected 3 times from all monkeys at 10-day intervals.
Total fecal bacteria as well as the levels of individual microbial popu-
lations in the feces (Bacteroidaceae, catenabacteria, bifidobacteria,
peptostreptococci, lactobacilli, streptococci, enterobacteria, Clostridia,
Veillonella, staphylococci) were reported to be equivalent between the
control monkeys and the sodium cyclamate metabolizing monkey at all
3 time points.
3.4. Neotame
Neotame was administered to male CD-1 mice (N=5 per group) via
gavage for 4weeks at a dose of 0.75mg/kg/day, and the control group
received only water (Chi et al., 2018). Fecal samples were collected for
16S rRNA gene sequencing and functional gene enrichment analysis
before and after 4 weeks of neotame exposure. Body weight did not
significantly differ between the 2 groups throughout the study and the
authors reported that “no difference of eating behavior or other beha-
viors were observed between two groups”. The relative fecal abundance
of Bacteroidetes significantly increased in the neotame exposed group,
which at the genus level was primarily due to elevated Bacteroides and
an undefined genus in family S24-7. The relative fecal abundance of
Firmicutes was significantly decreased following neotame exposure,
with over 12 genera altered, most notably multiple components of the
Lachnospiraceae and Ruminococcaceae families, such as Blautia, Dorea,
Oscillospira, and Ruminococcus. Despite these changes in the gut mi-
crobiome following neotame exposure, some limitations are discussed
by the authors including the use of a neotame dose 2.5x the human ADI
and the small sample size, and the authors indicate that long-term
studies in humans should be conducted.
3.5. Saccharin
A few studies were identified reporting effects of saccharin on the
gut microbiota. An early study (Anderson and Kirkland, 1980) was
conducted in male rats provided chow containing no saccharin (control;
N= 5) or 7.5% sodium saccharin (N=7) for 10 days. Final average
saccharin intake was 10–14 g/kg/day. At the end of the 10-day study,
the cecum was collected from each rat and weighed, and microbial
contents were analyzed by culturing the aerobic and anaerobic bacteria.
The cecal populations of the saccharin-fed rats contained increased
numbers of aerobes and equivalent numbers of anaerobes compared to
the control group, leading to a downward shift in the anaerobe/aerobe
ratio. Furthermore, saccharin consumption was reported to prevent the
growth of saccharin-sensitive anaerobes in the gut. Given that the
average daily saccharin intake was approximately 2000 times higher
than the 5mg/kg/day ADI set by regulatory authorities for saccharin,
the human dietary relevance of this study is evidently limited.
Suez et al. (2014) reported a small clinical investigation in 7 healthy
adults who did not normally consume low-calorie sweeteners. Subjects
consumed 5mg/kg/day of saccharin in 3 divided daily doses of ap-
proximately 120 mg/dose for 1 week. No control group was included in
the study and only single-day baseline measurements were obtained.
Fecal samples were collected, glucose tolerance tests were conducted
daily, and the microbiota was analyzed by 16S rRNA analysis. The data
were statistically assessed by creating data groups based on scientific
outcomes, as opposed to being based on study design, which is parti-
cularly difficult to understand with such a small sample size. Specifi-
cally, the measured glycemic responses were used to classify the sub-
jects as either “responders” (4 subjects that had elevated glycemic
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responses at Day 5 and after) or “non-responders” (3 subjects that
showed no change in glycemic response). The authors reported that the
microbiome configurations of the responders were found to cluster
differently from the non-responders both before and after saccharin
consumption. Pronounced compositional changes were observed in the
responder's microbiomes over the study week, whereas no changes
were reported in the non-responders. Despite these measured differ-
ences between the microbiomes of the 2 groups, the arbitrary grouping
criteria and lack of control group bring into question the biological
significance of these reported findings. The lack of controlling for ha-
bitual diet may be a driving factor behind the reported gut microbial
changes, which is supported by the fact that the composition of the gut
microbiota of the responder and non-responder groups was already
different prior to saccharin consumption (see Day 1, Fig. 1). Since the
responder and non-responder populations were not comparable on Day
1 of the analysis, it therefore would have been more appropriate to
compare each subject back to their own multi-day baseline to detect
any saccharin-associated changes.
Suez et al. (2014) also evaluated effects of saccharin in mice. The
commercial saccharin preparation, Sucrazit (5% saccharin, 95% glu-
cose), was administered in the drinking water to C57Bl/6 male mice
(N=20 per group) for 11 weeks at a saccharin dose of approximately
3333mg/kg/day (about 650 times higher than the ADI of 5mg/kg/
day). At the end of the study, an OGTT was conducted in all mice and
fecal samples were collected for 16S rRNA analysis from 5 out of 20
mice in the saccharin group as well as each of the control groups. While
glucose was reported to be statistically significantly increased in the
treated mice (Suez et al., 2015), and this difference was not found when
mice were treated with antibiotics, as noted above, this is not a measure
of an effect on gut microbiota and therefore any cause and effect re-
lationships can only be speculative. Moreover, based on fluid intake
data reported, albeit limited to a subset of the mice studied, it appears
that antibiotic treatment may have been greater in the saccharin versus
control mice, which makes data interpretation more problematic. Ad-
ditionally, from the data reported, it appears that the blood glucose
area under the curve (AUC) following the OGTT was increased in only 3
of the 20 mice studied, and no baseline OGTT was available for com-
parison. The majority of data points (∼17 out of 20), though, were
found to fall within the range of control measurements. No direct sta-
tistical analysis was provided for saccharin treatment alone and as such
it is unclear if there is truly a significant difference between the sac-
charin-treated animals and the controls. The reason for this postulated
altered glycemic response in this limited number of animals is unclear,
as in addition to being exposed to saccharin, chow consumption was
reported to be unequal between the groups. Although food intake was
measured for only a subset of mice (4 out of 20) over a portion of the
study (3 days at the end of the study), instead of for all mice throughout
the entire study, such differences in food intake alter the consumption
levels of fiber, protein, fat, and carbohydrates, which directly influence
blood glucose measurements. These differences in chow consumption
could also have an effect on the composition of gut microbiota.
With regard to the fecal analyses conducted, the authors reported
treatment-related alterations in the abundance of numerous operational
taxonomic units (± 1.2-fold), including increases in the relative
abundance of the Bacteroides genus and the Clostridiales order, and
decreases in Lactobacillus reuteri, as well as other members of the
Clostridiales order. It is difficult to interpret the results of these findings,
for a variety of reasons. First, the treated mice received water with a
commercial saccharin formulation, not pure saccharin. This means
there was 11 weeks of exposure to a nutritive sweetener (carrier sub-
stance for the commercial saccharin formulation) in the drinking water
of the treated mice, where control mice received only water. Second,
the study reported between-group differences in both water and solid
food consumption that, irrespective of caloric considerations, can in-
troduce physiologic factors that could influence gut microbiota popu-
lations. Third, the data on gut microbiota changes are from only a
subset of the population, about which there is no specific information
on food or water intake. In all, it is not possible to know whether be-
tween-group differences observed in the gut microbiota measures are
reflective of changes in diet and/or nutrient and/or fluid intake or
changes related to the presence of saccharin. Finally, the saccharin dose
delivered was far above expected human intakes.
In this same publication, Suez et al. (2014) did report other in-
vestigations in mice treated with pure saccharin. Saccharin was ad-
ministered for 5 weeks in the drinking water at a concentration of
0.1 mg/mL (N=20), leading to a daily exposure of about 5mg/kg. In
contrast to the previous study, both liquid and chow consumption were
reported to be equivalent between the 2 groups; however, the data
again represented only a subset of the population (8 out of 20 mice per
group). This snapshot of food and water consumption may or may not
be representative of average consumption in all animals over the entire
length of the study. OGTTs were conducted and fecal samples were
collected at the end of the 5-week study. Glycemic response was sig-
nificantly higher in the saccharin-exposed mice, albeit with high
variability in the range of responses of the individual animals; about
half (N=10) were within the range of control responses (AUC≈18 to
44× 103) whereas the other half were above of this range (AUC≈45
to 56×103). The fecal samples were transplanted into germ free mice
(N=16 per group) via gavage, but no information was provided as to if
the fecal samples were collected from all 20 animals and then pooled, or
if only select animals were chosen as donors. The fecal-recipient mice
were provided with standard rodent chow and water for 6 days, at
which point OGTTs were conducted and fecal samples were collected
for 16s rRNA analysis. The investigators report an “impaired glucose
tolerance” in the germ-free mice implanted with fecal samples from
saccharin-treated versus control mice. It is difficult to determine, how-
ever, if there is actually a treatment-related effect. The study found
statistically significant increases in the post-OGTT glucose level at 30,
60, and 90min; however, (a) baseline blood glucose level was statisti-
cally significantly higher in the saccharin-fecal recipients versus control-
fecal recipients and the later observed differences were small, which
may mean that the later differences were wholly unrelated to treat-
ment; (b) total glucose AUC was not reported and may not be sig-
nificantly different between the 2 groups; (c) peak blood glucose levels
were not different for the 2 groups of mice; and (d) there was no
baseline OGTT for comparison to understand potential intra-group/
intra-individual variability with glucose response to an OGTT. As a
result, it is difficult to conclude from this single OGTT result that gut
microbiota from saccharin-treated mice affected a transference of
Fig. 1. Order-level relative abundance of taxa samples reproduced from Suez
et al. (2014), Figure 4f. Adapted by permission from Macmillan Publishers Ltd:
Suez et al. (2014). A clinical investigation was conducted in 7 subjects con-
suming 5mg/kg/day of saccharin for 7 days. Subjects were classified as non-
responders or responders, based on having no change or elevated glycemic
responses, respectively, following saccharin consumption. Fecal 16S rRNA was
measured on Day 1 (baseline) and on Day 7.
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“impaired glucose tolerance” to germ-free mice. In the evaluations of
actual changes in gut microbiota, the abundance of only a few opera-
tional taxonomic units were reported when the saccharin-recipient and
control-recipient fecal microbiota were compared (± 1.2-fold). A few
increases in relative abundance were observed in the Bacteroides genus
and the Lactobacillus reuteri species, and decreases were mainly ob-
served in a few members of the Clostridiales order and Ruminococcaceae
family. These changes are not clearly known to be ones that can elicit a
change in the ability of mice, or humans, to appropriately process a
bolus load of glucose.
For an additional 4 weeks, 10 mice per group were given ad libitum
access to food and water with 0 or 5mg/kg/day pure saccharin, and
with or without antibiotic (Gram-negative-targeting antibiotics cipro-
floxacin [13mg/kg/day] and metronidazole [67mg/kg/day]). The re-
sults showed a similar response to the OGTT for the saccharin and
control-treated mice when exposed to an antibiotic, from which the
authors concluded that changes in gut microbiota were causative in the
increased blood glucose levels seen when the mice received water with
saccharin versus plain water. As discussed above, a potential difference
in baseline fasting levels is not considered in this conclusion and intra-
individual differences may account for the responses. In addition, it is
unclear if antibiotic exposure was equivalent in the different treatment
groups and there is also no information regarding how animals were
selected to continue with the antibiotic-arm of the study. With the in-
dividual differences reported in glycemic response, this should have
been reported.
Bian et al. (2017b) recently conducted a study in mice over a 6-
month period, where C57BL/6J male mice were exposed to saccharin in
the drinking water (0.3mg/mL) or consumed just water (N= 10 per
group). Water consumption was monitored and the authors stated that
the exposure to saccharin was equivalent to the ADI of 5mg/kg; how-
ever, the consumption data was not published. In the absence of the
liquid consumption data, based on the average weight of the mice at the
beginning and end of the study (23–33 g) and the usual daily water
consumption of a mouse (∼3–5mL), it appears that daily exposure was
more likely between 27 and 65mg/kg (at least ∼5x the ADI). Fecal
samples were collected at baseline, 3, and 6 months for 16S rRNA
analysis and the authors reported that 11 genera were significantly
altered following saccharin exposure (i.e., Sporosarcina, Jeotgalicoccus,
Akkermansia, Oscillospira, and Corynebacterium increased at 3 months;
Corynebacterium, Roseburia, and Turicibacter increased at 6 months;
Anaerostipes and Ruminococcus decreased at 3 months; Ruminococcus,
Adlercreutzia, and Dorea decreased at 6 months). Given the suspected
high exposure to saccharin, and the lack of food consumption data, the
significance of these findings is unclear.
Two studies have investigated the impact of adding SUCRAM (sac-
charin + neohesperidin dihydrochalcone [NHDC]) to piglet feed. In the
first study, feed containing 0.015% SUCRAM was fed to male and fe-
male suckling Landrace X Large White piglets for 2 weeks (N = 8, mg/
kg/day dose not reported) (Daly et al., 2014). Control piglets (N= 8)
consumed regular feed. Cecal and rectal contents were collected at the
end of the study and the microbiota was evaluated by 16S rRNA ana-
lysis. A significant increase (2.5-fold) in the relative population size of
Lactobacillus in the cecum was reported in the piglets fed SUCRAM
compared to control, and 1 Lactobacillus phylotype, OTU4228, was
found to be predominantly responsible for this elevation. In the second
study, the same experimental conditions were employed, with the ad-
dition of treated and control groups containing male and female
Gloucester Old spot piglets (Daly et al., 2016). Similar to the findings of
the first study, significant increases in the population abundance of the
Lactobacillaceae family was measured in the cecal contents of both
piglet strains fed SUCRAM, as well as significantly lower abundances of
the Veillonellaceae and Ruminococcaceae families. The authors noted
that based on the control groups used in their studies, it was unclear if
the observed changes were due to saccharin or NHDC. To address this,
they conducted in vitro tests to gain a better understanding of the
mechanism of Lactobacillaceae enhancement following SUCRAM con-
sumption. Lactobacillus phylotype 4228 was isolated from the intestine
of the piglets, and the growth characteristics of this strain were ob-
served in the presence of saccharin or NHDC, independently. The pre-
sence of saccharin had no effect on the growth of Lactobacillus 4228 in
vitro, whereas NHDC present in the media at 0.5mM significantly de-
creased the lag phase of Lactobacillus 4228 growth when switching from
glucose-containing medium to lactose, sucrose, or fructose. Based on
these data, the authors concluded that it appears that the NHDC com-
ponent of SUCRAM, not saccharin, is responsible for the changes in
Lactobacillaceae prevalence in vivo. Further studies have also been re-
cently conducted to characterize the mucosa-associated microbiota
along the entire length of the piglet intestinal tract and the effects of
SUCRAM exposure (Kelly et al., 2017).
3.6. Sucralose
The study published by Suez et al. (2014), also asserted that su-
cralose affected the gut microbiome, based on a reported increase in
glucose response to a single OGTT in mice receiving a commercial
formulation of sucralose (Sucralite, 5% sucralose) in the drinking water
for 11 weeks (approximately 1666mg/kg sucralose per day), because a
similar effect was not seen when the mice were treated with antibiotics.
The lack of change in the post-prandial response to the OGTT when
sucralose-treated mice were given antibiotics is insufficient evidence to
conclude that there was an effect on the gut microbiota. There was also
no actual measure of microbiota in the mice that consumed sucralose,
so the study presents no evidence of an effect of sucralose on the mi-
crobiota.
In an article investigating artificial sweeteners and Crohn's disease,
mice with Crohn's disease-like ileitis SAMP1/YitFc (SAMP), were ad-
ministered Splenda® (sucralose:maltodextrin, 1:99, w/w) in the
drinking water at concentrations of 0 or 1.08mg/mL for 6 weeks
(N=6 per group) (Rodriguez-Palacios et al., 2018). Body weight was
monitored and fecal samples were collected at the end of the study and
analyzed by microbiological culturing. Culture data reported elevated
levels of E. coli in the feces of the Splenda®-exposed mice and no
changes in lactobacilli, total bacteria, or anaerobic clostridial species
between the Splenda® and control SAMP groups. In the second study,
SAMP mice and parental ileitis-free AKR/J (AKR) control mice were
administered Splenda® in the drinking water at concentrations of 0 or
3.5 mg/mL for 6 weeks (N=6 per group). Fecal samples were collected
at the end of the study and analyzed by 16S rRNA analysis. Splenda®
exposure in both SAMP and AKR mice significantly elevated the levels
of the Proteobacteria phylum by increasing the Alphaproteobacteria, Be-
taproteobacteria, Epsilonproteobacteria, Deltaproteobacteria, and Gamma-
proteobacteria classes. Splenda® reduced the levels of other phyla, such
as lactobacilli and clostridia, with no overall impact on Bacteroidetes or
Firmicutes. Based on histological analyses, the authors noted that
Splenda® did not increase the severity of ileitis in the SAMP mice. Al-
though no details were provided on monitoring food or water con-
sumption, nor the daily exposure to Splenda® on a body weight basis,
the authors did indicate that the 3.5mg/mL concentration was
equivalent to the maximum United States Food and Drug Administra-
tion (FDA)-approved dose, suggesting the doses in both studies were no
greater than 5mg/kg bw/day. Whether or not the microbial changes
reported in the mice with Crohn's disease-like ileitis and the ileitis-free
mice are due to sucralose itself cannot be determined as no controls
were included in this study to separate out the components of Splenda®,
which is primarily composed of the bulking agent maltodextrin. In
addition to a lack of control for ingredients other than sucralose in the
test material, it is also not clear if food consumption was equivalent
between groups, which could affect measures of gut microbiota species.
Uebanso et al. conducted a study with male C57Bl/6J mice (N=8
per group) and exposed them to low-dose (1.5mg/kg/day) or high-dose
(15mg/kg/day) sucralose in the drinking water for 8 weeks (Uebanso
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et al., 2017). Control mice received distilled water, and the authors
measured body weight and fluid intake and reported an average ex-
posure to sucralose of 1.4mg/kg/day for the low-dose and 14.2mg/kg/
day for the high-dose groups. Liquid and energy consumption was
monitored and reported to be equivalent between the control and su-
cralose groups. Fecal samples were obtained at the end of the study for
16S rRNA analysis, and the relative amounts of total bacteria, Firmi-
cutes, and Bacteroidetes, Bacteroides, and Clostridium IV, were equivalent
between all groups. The relative amount of fecal Clostridium IVXa,
however, was reported to decrease significantly in the sucralose groups
in a dose-dependent manner. Other analyses were conducted, to see if
other sucralose-dependent changes were present in the gut microbiome,
but the relative band intensities of different 16S rRNAs from the V2 and
V3 region, and principal component analysis and hierarchical clustering
did not differ between the groups.
Bian et al. (2017c) conducted a study in mice over a 6-month
period, where C57BL/6J male mice were exposed to sucralose in the
drinking water (0.1mg/mL) or consumed just water (N= 10 per
group). Water consumption and body weight were monitored. The
authors stated that the calculated exposure to sucralose was within the
U.S. FDA ADI of 5mg/kg; however, these data were not provided. In the
absence of the liquid consumption and body weight data, assuming an
average body weight range of 23–33 g (as reported in the Bain et al.,
(2017a, b, c) study with saccharin that used the same strain, sex, and
age of mice) and usual daily water consumption of ∼3–5mL, it appears
that daily exposure was more likely between 9 and 22mg/kg (at
minimum ∼2x the FDA ADI). Fecal samples were collected at baseline,
3, and 6 months for 16S rRNA analysis and the authors reported that 14
genera were significantly altered following sucralose exposure (i.e.,
Ruminococcus increased at 3 months; Turicibacter, Roseburia, Akker-
mansia, Clostridiaceae, and Christensenellaceae increased at 6 months;
Anaerostipes, Ruminococcus, Staphylococcus, Peptostreptococcaceae, and
Bacillales decreased at 3 months; Ruminococcus, Streptococcus, Dehalo-
bacterium, and Erysipelotrichaceae decreased at 6 months). Food con-
sumption was not monitored, so it is unclear if dietary intake was
standardized between the groups, and the sucralose exposure level was
not clearly defined. The significance of the findings reported in this
study regarding the gut microbiota, therefore, are unclear.
In a 12-week study in male Sprague-Dawley rats (N=10 per
group), Splenda® (1.10% sucralose, 1.08% glucose, 4.23% moisture,
and 93.59% maltodextrin) was dissolved in the drinking water at the
following doses: 0, 100, 300, 500, or 1000mg/kg/day (equivalent to
1.1, 3.3, 5.5, 11mg/kg/day sucralose) (Abou-Donia et al., 2008). Fecal
samples were collected weekly, fecal weights were recorded on a wet
basis, and bacteriological analysis was conducted by subculturing fecal
bacteria. Following 12 weeks of Splenda® exposure, the numbers of
total anaerobes, bifidobacteria, lactobacilli, and Bacteroides sig-
nificantly decreased in all Splenda® groups compared to control. At the
3 highest Splenda® doses, the abundance of Clostridia and total aerobic
bacteria also decreased significantly. The comparison of the bacterial
count data between groups, however, appears to be limited in value as
it was not indicated that the counts were standardized appropriately
based on water intake. Water consumption has a marked effect on stool
formation and moisture content in the feces, and since the fecal weights
were reported on a wet basis, this should have been accounted for when
evaluating the bacterial counts. Moreover, significant differences in
body weight were reported between the Splenda® and control groups
but no data reporting food intake, energy consumption, or water intake
were presented. Similar to the study with Splenda® in mice described
above, no control groups were included to separate out the effects of the
individual components of Splenda®, particularly the maltodextrin. The
relevance of these reported changes in the microbial composition of the
gut following Splenda® ingestion, therefore, is questionable. Indeed, an
Expert Panel that thoroughly evaluated this study concluded that it was
deficient in several critical areas and that its results cannot be inter-
preted as evidence that either Splenda®, or sucralose, produced adverse
effects in the rats studied, including effects on the gastrointestinal mi-
crobiota (Brusick et al., 2009).
Two recently published conference abstracts that reported measures
of the microbiome in animals exposed to sucralose met the defined
search criteria and therefore were included in the search results. In the
first study, differences in intestinal microbiota composition in gut
hormone peptide YY (PYY) knockout and wildtype male mice were
investigated under basal conditions and following exposure to sucralose
(1%) in drinking water for 1 week (Farzi et al., 2017). At the phylum
level, baseline fecal microbial composition was reported to be similar,
with decreased Bacteroidetes in the wildtype mice following exposure to
sucralose that was attenuated in the PYY-knockouts. In the second
study, the impact of pre- and post-natal exposure to sucralose combined
with acesulfame-K was investigated (Olivier-Van Stichelen et al., 2017).
Pregnant mice consumed sucralose/acesulfame-K mixed in the diet (no
dose reported) and continued to consume this same diet after pups were
born. The authors presumed that pups were exposed to the sweeteners
through placental circulation and breastmilk, but this was not con-
firmed experimentally nor was the length of exposure reported. The
mucin-feeding bacteria Akkermansia muciniphila was noted to “dis-
appear” in 19-day old pups exposed to the sweeteners compared to
control, along with an increase in Firmicutes. Additional study design
details, such as LNCS exposure on a mg/kg basis, and food/water
consumption data, are required in order to comment on the direct re-
levance of these microbiome findings to LNCS consumption.
3.7. Rebaudioside A
The impact of rebaudioside A ingestion on the gut microbiota has
been investigated in 1 study, where SPF BALB/c mice were orally ad-
ministered rebaudioside A for a total of 4 weeks at a low dose of 5.5mg/
kg/day (N=5) or a high dose of 139mg/kg/day (N=5), and distilled
water was used as control (N= 5) (Li et al., 2014). Total viable cell
counts were obtained in the feces over the 4-week study period, and
Enterobacteriaceae and lactobacilli were measured at the end of the
study by denaturing gradient gel electrophoresis. Rebaudioside A con-
sumption, at both the low and high doses, was not associated with any
significant changes in the total number of anaerobic bacteria, en-
terococci, enterobacteria, or lactobacilli and also had no effect on En-
terobacteriaceae distribution. A significant increase was found in the
diversity of lactobacilli species present in the feces, yet, given that this
dose (46mg/kg/day steviol equivalents) was more than 10-fold higher
that the ADI of 4mg/kg/day steviol equivalents, the human dietary
relevance of this change is limited. Overall, the results at the lower dose
of 1.8mg/kg/day steviol equivalents indicate that the gut microbiota of
mice was not affected by rebaudioside A consumption.
3.8. Undefined low/no-calorie sweeteners
Suez et al. (2014) conducted a cohort study in 381 non-diabetic
individuals (44% males, 56% non-pregnant females, age 43.3 ± 13.2)
that were participating in an ongoing clinical nutrition study. Para-
meters assessed during the clinical nutrition study included body mass
index, body circumference, fasting glucose levels, complete blood
counts, and general chemistry parameters. Subjects completed vali-
dated long-term food frequency questionnaires that included specific
questions regarding artificial sweeteners and the authors indicated that
they were able to quantify long-term non-caloric artificial sweetener
(NAS) consumption directly from these answers. Based on this, subjects
were classified as either ‘high-consumers’ (N= 40) or ‘non-consumers’
(N= 236), yet, no details were provided on the exact criteria used to
establish this grouping nor was the exclusion of 105 ‘low-consumer’
subjects explained. No information was provided on the types or
amounts of NAS consumed by the 40 subjects identified as high-con-
sumers and diet was not controlled for. The Spearman correlation test
was used to conduct a non-parametric rank comparison of glycosylated
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hemoglobin (HbA1C %) levels between the high- and non-consumers
and was reported to be significantly higher in the high-consumer group.
A brief look at the data (Fig. 2) indicates that some of the non-con-
sumers had higher HbA1C values than the high-consumers and that all
values for the high-consumers fell within the range of the non-con-
sumers, suggesting that the difference may simply be due to the much
lower sample size of high-consumers. Additionally, no explanation was
provided to justify the use of a non-parametric test despite all the
measurements appearing to be parametric. The authors proceeded to
randomly select 172 individuals out of this cohort (N=276) and
characterize their fecal bacterial 16S rRNA, but no further details were
provided on collection of the fecal samples. A parametric Pearson
correlation test was conducted to identify correlations between taxo-
nomic entities within the fecal microbiota and NAS consumption. The
authors identified several significant positive correlations between the
Enterobacteriaceae family, the Deltaproteobacteria class, as well as the
Actinobacteria phylum, and NAS consumption, yet, in the absence of
information on habitual diet and amount or type of sweetener con-
sumed, it is not possible to draw any conclusions regarding the impact
of NAS on the gut microbiota.
4. Common critical issues when measuring the gut microbiome
Following review of the studies of LNCS that included evaluations of
gut microbiota, certain critical issues were found to be common among
the whole. The most common problem was the lack of proper control
groups, particularly isocaloric controls. As outlined, dietary factors are
key determinants in gut microbial composition, and as discussed in
Section 2, differences in the types of food consumed (i.e., plant-versus
animal-based) and overall caloric intake lead to distinctly diverse gut
microbiomes (David et al., 2014). To obtain meaningful outcomes in
clinical studies aimed at measuring the response of the gut microbiota
to low-level ingredient exposure, it is critical that background dietary
consumption also be strictly controlled. Of the 3 clinical investigations
assessed, none were designed to account for habitual dietary con-
sumption (Suez et al., 2014; Frankenfeld et al., 2015). As such, any
reported changes in the gut microbiota in these clinical studies could
very likely be due to dietary differences between LNCS-exposed and
non-exposed groups, and not necessarily the LNCS itself. It is much
easier to control dietary composition in animal studies through the
provision of standardized animal chow, and to effectively achieve this,
food consumption must be monitored throughout the study, particu-
larly if LNCS are mixed within the food, as caloric intake independently
affects the composition of the gut microbiota. In the aspartame study in
rats conducted by Palmnäs et al. (2014), for example, food intake was
appropriately monitored and the authors did find that food consump-
tion in the aspartame groups was significantly less than the controls.
The authors, however, did not discuss these results in the context of
possible effects on the gut microbiota and as such, the changes that
were reported in microbial composition are likely to be related to these
differences in caloric intake. Similar discrepancies in chow and liquid
intake were reported in the 11-week mouse study by Suez et al. (2014),
where addition of high concentrations of the commercial sweeteners
aspartame, saccharin, and sucralose to the drinking water led to large
variances in consumption between the sweetener and control groups.
Despite the fact that these differences likely introduced significant
confounding effects into measures of the gut microbiota, they were not
discussed or factored into any conclusions drawn by the authors.
Another critical study design deficiency noted in a number of the
animal studies was the use of LNCS doses that were greater than the
currently established ADIs. In 2 studies in particular, doses in excess of
500 times higher than the ADI were utilized. Saccharin was adminis-
tered to rats at doses of at least 10000mg/kg/day in the study by
Anderson and Kirkland (1980), which is 2000 times higher than the ADI
of 5mg/kg/day for saccharin. Similarly, Suez et al. (2014) fed mice
doses of saccharin that were about 600 times higher than the ADI,
equivalent to approximately 3333mg/kg/day in the drinking water. It
is well-documented to date that saccharin administered at high doses to
rats does alter the gut microbiota, and the study by Anderson and
Kirkland (1980), in fact, was one of the first publications to report these
findings. In addition to the increased total number of aerobic microbes
present in the cecal contents reported by Anderson and Kirkland
(1980), a number of other gut-associated changes have been reported in
rats fed high doses of saccharin, including marked enlargement of the
cecum, increased stool sizes, as well as significant changes in the me-
tabolism of amino acids by the gut microbiota leading to increased
urinary excretion of the microbial metabolites indican and ρ-cresol and
decreased excretion of phenol (Anderson and Kirkland, 1980; Lawrie
et al., 1985; Lawrie and Renwick, 1987; Sims and Renwick, 1983). The
fact that Suez et al. (2014) reported that high doses of saccharin in mice
induced changes in the composition of the gut microbiota is not novel
given the already well-established association in rats. Prior to the es-
tablishment of the saccharin ADI, some clinical investigations were
conducted at doses higher than 5mg/kg/day to confirm its safe con-
sumption and to ensure that the gut-associated changes in amino acid
metabolism observed in rats were not present in humans. For instance,
333mg of saccharin was administered to 15 non-saccharin consuming
volunteers (3 females, 12 males, average age 27.5 years) 3 times per
day, equivalent to a daily dose of 14mg/kg/day, for a period of 4
weeks. Subjects were instructed to consume their regular diet during
the study and urine samples were collected before, during, and after
saccharin exposure and analyzed for indican, ρ-cresol, and phenol
content. Contrary to what was observed in rats, average urinary levels
of these 3 microbial metabolites were unchanged following chronic
saccharin consumption compared to baseline control (Lawrie and
Renwick, 1987; Roberts and Renwick, 1985). This disparity between
the effects reported at high doses in rats and the lack of changes re-
ported in humans highlights the importance of utilizing biologically
relevant doses in these types of investigations. The changes in the ro-
dent gut microbiota in response to high doses of saccharin reported by
Suez et al. (2014) and Anderson and Kirkland (1980) represent bio-
chemical and physiological changes and cannot be extrapolated to
humans who are exposed to profoundly lower levels in the diet. To date,
dietary saccharin is associated with a safe toxicity profile in humans,
and even the earliest clinical studies that were conducted at much
higher doses in diabetic patients (4.8 g/day of saccharin for 5 months)
were not associated with any adverse effects (JECFA, 1982).
A few of the animal studies, including the investigation of Splenda®
consumption in SAMP and AKR mice (Rodriguez-Palacios et al., 2018),
and the piglet studies with SUCRAM (Suez et al., 2015), did not provide
sufficient information to convert LNCS consumption to exposures based
Fig. 2. Glycosylated hemoglobin (HbA1C %) levels reproduced from Suez et al.
(2014), Figure 4a. Adapted by permission from Macmillan Publishers Ltd: Suez
et al. (2014). HbA1C% levels of non-consumers of non-caloric artificial
sweeteners (NAS) (N=236) compared with high-consumers (N=40) reported
in a clinical nutrition study of non-diabetic individuals (N= 381).
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on body weight (i.e., body weight of animals, food consumption by
weight, water consumption by volume). In the absence of this in-
formation, it is not possible to comment on the relevance to humans in a
dietary context, highlighting another common critical issue in the
conduct of these studies. Of the animal studies that did employ LNCS
doses that were equal to or less than the respective ADIs, the majority of
studies reported no changes in the gut microbiota that could be defi-
nitively linked to sweetener consumption based on the study details
provided. For instance, administration of rebaudioside A to mice at a
dose of 1.8mg/kg/day steviol equivalents, which is less than the ADI of
4mg/kg/day steviol equivalents, was not associated with any sig-
nificant changes in numbers of anaerobic bacteria nor alterations in the
composition of the gut microbiota (Li et al., 2014) and likewise, ace-
sulfame K exposure of 12.9 mg/kg/day for 8 weeks in mice had no ef-
fect on the fecal microbiome (Uebanso et al., 2017). Although Palmnäs
et al. (2014) administered aspartame to rats at doses lower than the ADI
of 40mg/kg/day (normal weight rats, 5 mg/kg/day; diet-induced obese
rats, 7 mg/kg/day), the findings from this study were inconclusive as
significant differences in water and food consumption between sweet-
ener and control groups were identified as confounding factors.
Splenda® was administered to rats by Abou-Donia et al. (2008) at 4
relevant sucralose doses that were all below the ADI of 5–15mg/kg/day
(1.1, 3.3, 5.5, and 11mg/kg/day), yet, the findings from this study
were limited due to the authors failure to standardize the fecal bacterial
count data or control for the bulking agent maltodextrin. In all, there
are only 3 studies in which a LNCS has been directly tested in vivo at
doses at or below the ADI that report a change in gut microbiota (Suez
et al., 2014; Bian et al., 2017c; Uebanso et al., 2017), all of which were
studies in mice, a species in which the level of reported changes in gut
microbiota may also have no relevance to human health.
As with all studies that aim to associate low level ingredient ex-
posure with a biological change or health outcome, utilizing well-de-
signed clinical investigations or relevant animal or in vitro models that
accurately reflect the appropriate human biological system is critical.
Methods for studying the human gut microbiome have evolved sig-
nificantly over the last decade and the establishment of rodent fecal-
transplant models has provided a suitable animal model with human
biological relevance to this field of study. The distal gut microbiota of
mice, for instance, is comprised of the same bacterial phyla as humans,
however, most of the bacterial genera and species present in mice do
not exist in the human gut (Turnbaugh et al., 2009). Germ-free mice
that are transplanted with human fecal microbiota, on the contrary,
establish a bacterial gut community that is reflective of humans, and it
is these types of animal models that have proven to be most informative
when studying the gut microbiome. Associations between obesity and
composition of the gut microbiota have been heavily investigated using
these models, and for example, it has been demonstrated that obese or
lean phenotypes can be transferred to germ-free mice through fecal
transplants from human individuals harboring these distinct pheno-
types (Xu and Knight, 2015). Only 1 publication was identified in our
literature search that utilized fecal transplant models (Suez et al.,
2014). The investigators in this case reported that impaired glucose
tolerance was transferable to germ-free mice that were the recipient of
feces obtained from saccharin-exposed mice (5mg/kg/day). As dis-
cussed in Section 3.4, however, the evidence of an “impaired glucose
tolerance” is questionable, and moreover, saccharin has been found to
have no effect on glucose control in humans (Ambrus et al., 1976).
5. Molecular and metabolic considerations
Both the chemical structures (Table 1) and in vivo metabolism of
approved LNCS support that they have no effect on the gut microbiota,
either as individual sweeteners or as a class. Aspartame for instance, is a
methyl ester of the dipeptide composed of the amino acids ʟ-aspartic
acid and ʟ-phenylalanine, that when ingested, is rapidly hydrolyzed by
gut esterases and peptidases to its amino acid components and
methanol. These metabolites are absorbed in the small intestine, and
neither aspartame nor its metabolites ever reach the colon for direct
interaction with the microbiota there (Magnuson et al., 2007; EFSA,
2013). Since the vast majority of gut microbiota resides in the large
intestine, potential effects of aspartame on gut microbiota are ex-
tremely limited. Numerous studies also show no effect of aspartame on
the gastrointestinal tract (Bianchi et al., 1980), indicating no deleter-
ious effects on the gut microbiota.
Metabolic studies in mice, rats, and humans with sucralose have
shown that this sweetener is largely unabsorbed, but not digested in the
gut, thus clearly demonstrating that it is not a substrate for gut mi-
crobiota. Research shows that there is no change in the metabolic
profile after prolonged exposure (> 1 year), indicating no microbial
metabolic adaptation, even with very high doses of orally consumed
sucralose (Roberts et al., 2000; Sims et al., 2000). Similarly, neither
saccharin nor acesulfame K, the potassium salt of 6-methyl-1,2,3-ox-
athiazine-4(3H)-one 2,2-dioxide, undergo gastrointestinal metabolism.
In contrast to sucralose, both of these latter sweeteners are rapidly
absorbed and excreted unchanged in the urine (McChesney and
Golberg, 1973; Byard et al., 1974; Volz et al., 1991). Early research on
each of these sweeteners, conducted in the assessment of their safety
prior to FDA approval of their use, also supports no adverse effect on
gut health or function, as evidenced by regulatory approvals worldwide
(JECFA, 1984; JECFA, 1991; JECFA, 1999). Therefore, there appears to
be no mechanism by which these LNCS can impact the microbiota in
such a way as to impact health.
The metabolic pathway for steviol glycosides that can be extracted
from the leaves of the Stevia rebaudiana plant directly involves the
hydrolyzing action of the intestinal microbiota. The molecular structure
of all steviol glycosides are similar, composed of a core steviol backbone
that is conjugated to different numbers and types of sugar moieties, and
these molecules, including stevioside and rebaudioside A, pass un-
absorbed through the upper portion of the gastrointestinal tract and
enter the colon intact (Koyama et al., 2003; Geuns et al., 2007). Once
reaching the colon, the sugar moieties attached to the steviol backbone
are sequentially removed by the gut microbiota, primarily of the Bac-
teroidaceae family (Gardana et al., 2003; Renwick and Tarka, 2008),
and thus represent an energy source to these microbiota. Any energy
contribution, however, is inconsequential, as total daily intake is very
low (Renwick, 2008), and thus, would not be expected to have any
meaningful effect on microbiota species involved in this metabolism.
All steviol glycosides yield the common backbone, steviol, following
removal of the conjugated sugars. Steviol is, itself, not a substrate for
the intestinal microbiota, and is absorbed from the colon virtually en-
tirely and intact. Following absorption, it is conjugated with glucuronic
acid, and primarily excreted in humans as steviol glucuronide via the
urine (Geuns et al., 2006; Wheeler et al., 2008). Furthermore, while gut
microbiota actively act upon steviol glycosides, recent research (Kelly
et al., 2017) showed that steviol glycosides, at levels comparable to the
ADI, had no impact on the gut microbiome. Cyclamate is also known to
be able to be metabolized by the gut microflora to cyclohexylamine,
albeit in a small percentage of the population (Renwick, 1986); how-
ever, exposure to cyclamate does not appear to adversely affect mi-
crobial distribution in the gastrointestinal tract (Matsui et al., 1976).
In general, all LNCS also have a high sweetening potency, which
means that dietary exposure will always be low - in milligram amounts -
and well below the levels known to be needed by other dietary con-
stituents to elicit a significant impact on the gut microbiome.
6. Conclusions
A review of the literature shows that the gut microbiota is able to be
impacted by many dietary factors and is likely changing on a day-to-day
basis. The science of how changes to the gut microbiota affect human
health is also still developing and not perfectly understood. The data
provide clear evidence that the major determinants of changes in
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microbiota numbers and phyla result from fairly large changes in in-
takes of different types of nutrients. The changes to the microbiota most
likely result from differing outcomes of metabolic processing of these
nutrients, resulting in different intra-colonic metabolic by-products,
possible changes in pH and osmotic character, and altered numbers and
proportion of phyla.
In contrast, studies of LNCS establish no clear evidence of any ad-
verse effect on the gut microbiota at doses relevant to human use.
Results of metabolism and safety studies show no evidence of a likely
mechanism for a clinically relevant effect on gut microbiota. The re-
ports of correlated effects primarily stem from studies where doses
employed are beyond the possible expected intakes of humans, where
there existed significant study design issues that make conclusions of
effects questionable, or where data were incorrectly evaluated/inter-
preted. A class-effect of LNCS on gut microbiota is similarly un-
supported by the data and no adverse health effects mediated by al-
terations of the gut microbiota can be assumed from the published
studies on this subject to date. Investigating how changes in the gut
microbiome affect human health is not an inconsequential process, and
therefore, studies evaluating the impact of food additive/ingredient
consumption on the microbiota need to be conducted in relevant animal
models or clinical populations at relevant exposure levels and be
carefully controlled to account for the presence of numerous con-
founding factors, including the habitual or background diet. The safety
databases that have been developed over decades for acesulfame K,
aspartame, saccharin, sucralose, and steviol glycosides, which are
structurally unrelated, indicate that these low or no-calorie sweeteners
as a group, or individually, pose no safety concerns at their currently
approved levels.
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